JohnPerentesisMDFAAP

Pediatric Hematology & Oncology • Cincinnati, OH

Pediatric Hematologic Oncology

Professor & Institute Director, Pediatric Oncology & Cancer Programs, Kleisinger Chair for New Cancer Treatments, Cincinnati Children's Hospital, University of Cincinnati College of Medicine

Join to view full profile

Dr. Perentesis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Perentesis' full profile

Already have an account?

Office
3333 Burnet Avenue
Ml 7015
Cincinnati, OH 45229
Phone+1 513-636-4266

Fax+1 513-636-3549
Is this information wrong?

Education & Training

University of Minnesota Medical SchoolPostdoctoral, Biochemistry/Oncology, 1986 - 1990
University of MinnesotaFellowship, Pediatric Hematology/Oncology, 1983 - 1986
University of MinnesotaResidency, Pediatrics, 1980 - 1983
University of Michigan Medical SchoolClass of 1980

Certifications & Licensure

OH State Medical License 2003 - 2026
MN State Medical License 1991 - 2007
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Fellow (FAAP) American Academy of Pediatrics

Clinical Trials

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Start of enrollment: 1998 Nov 01
Terminated
Phase 1
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Start of enrollment: 2004 Mar 25
Recruiting
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Start of enrollment: 2005 Oct 01
Completed
Phase 1
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Start of enrollment: 2007 Mar 26
Active, not recruiting
Phase 3
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Start of enrollment: 2008 Feb 04
Active, not recruiting
Phase 3
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
Recruiting
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 3
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
Active, not recruiting
Phase 3
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas Start of enrollment: 2010 Jul 10
Completed
Phase 2
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
Active, not recruiting
Phase 3
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 1
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients Start of enrollment: 2012 Jun 01
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors Start of enrollment: 2012 Jun 27
Active, not recruiting
Phase 2
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Start of enrollment: 2012 Sep 01
Completed
Phase 2
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2012 Nov 14
Completed
Phase 1
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Start of enrollment: 2013 Nov 01
Completed
Phase 1
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2013 Jan 31
Completed
Phase 1, Phase 2
AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2013 Sep 17
Completed
Phase 1
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia Start of enrollment: 2013 Jun 24
Completed
Phase 2
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Start of enrollment: 2013 Sep 03
Completed
Phase 1
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2014 Mar 28
Completed
Phase 1, Phase 2
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Start of enrollment: 2014 May 16
Completed
Phase 1, Phase 2
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01
Completed
Phase 1
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 01
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11
Completed
Phase 1
Registry for Proton Beam Radiation Therapy Start of enrollment: 2013 Dec 18
Completed
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
Impact of Multiple Beams on the FLASH Effect in Soft Tissue and Skin in Mice.
Anthony Mascia, Shelby McCauley, Joseph Speth, Stefanno Alarcon Nunez, Gael Boivin, Marta Vilalta, Ricky A Sharma, John P Perentesis, Mathieu Sertorio> ;International Journal of Radiation Oncology, Biology, Physics. 2024 Jan 1
2 citations
HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma.
Matthew C Garrett, Rebecca Albano, Troy Carnwath, Lubayna Elahi, Catherine A Behrmann, Merissa Pemberton, Daniel Woo, Eric O'Brien, Brett VanCauwenbergh, John Perentes...> ;Scientific Reports. 2023 Aug 1
Correction to: Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR).
Andrew Roehrig, Daniel J Indelicato, Arnold C Paulino, Ralph Ermoian, William Hartsell, John Perentesis, Christine Hill-Kayser, Jae Y Lee, Nadia N Laack, Victor Mangon...> ;Journal of Neuro-Oncology. 2023 Aug 1
2 citations
Ultra-high dose-rate proton FLASH improves tumor control.
Samriddhi Shukla, Taniya Saha, Nihar Rama, Anusha Acharya, Tien Le, Fenghua Bian, Johnny Donovan, Lin Abigail Tan, Ralph Vatner, Vladimir Kalinichenko, Anthony Mascia,...> ;Radiotherapy and Oncology. 2023 Sep 1
Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR).
Andrew Roehrig, Daniel J Indelicato, Arnold C Paulino, Ralph Ermoian, William Hartsell, John Perentesis, Christine Hill-Kayser, Jae Y Lee, Nadia N Laack, Victor Mangon...> ;Journal of Neuro-Oncology. 2023 Apr 1
3 citations
Barriers to medication adherence among adolescents and young adults with cancer.
Meghan E McGrady, Tyler G Ketterl, Robin E Norris, John P Perentesis, Daniel Pettee, Constance A Mara, Gabriella Breen, Ahna L H Pai> ;Pediatric Blood & Cancer. 2023 Mar 1
2 citations
Data standards in pediatric oncology: Past, present, and future.
Kirk D Wyatt, David H Noyd, Nicole M Wood, Charles A Phillips, Tamara P Miller, Elyssa M Rubin, Lena E Winestone, Angela J Waanders, John P Perentesis, Richard Aplenc> ;Pediatric Blood & Cancer. 2023 Feb 1
2 citations
Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy.
Jonathan D Bender, Jeremy D Rubinstein, Benjamin Mizukawa, John P Perentesis, Lauren Pommert> ;Pediatric Blood & Cancer. 2023 Apr 1
15 citations
FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases (FAST-01): Protocol for the First Prospective Feasibility Study.
Emily C Daugherty, Anthony Mascia, Yong Zhang, Eunsin Lee, Zhiyan Xiao, Mathieu Sertorio, Jennifer Woo, Claire McCann, Kenneth Russell, Lisa Levine, Ricky Sharma, Deep...> ;JMIR Research Protocols. 2023 Jan 5
63 citations
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial.
Anthony E Mascia, Emily C Daugherty, Yongbin Zhang, Eunsin Lee, Zhiyan Xiao, Mathieu Sertorio, Jennifer Woo, Lori R Backus, Julie M McDonald, Claire McCann, Kenneth Ru...> ;JAMA Oncology. 2023 Jan 1
13 citations
Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis.
Zaili Luo, Mingyang Xia, Wei Shi, Chuntao Zhao, Jiajia Wang, Dazhuan Xin, Xinran Dong, Yu Xiong, Feng Zhang, Kalen Berry, Sean Ogurek, Xuezhao Liu, Rohit Rao, Rui Xing...> ;Nature. 2022 Dec 1
2 citations
US News & World Report and quality metrics: Inclusion of sickle cell disease is a matter of equity.
Alexandra Power-Hays, Christopher E Dandoy, Angela Lorts, John P Perentesis, Ndidi Unaka, Russell E Ware, Patrick T McGann> ;Pediatric Blood & Cancer. 2022 Aug 1
8 citations
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia.
Laura Barreyro, Avery M Sampson, Chiharu Ishikawa, Kathleen M Hueneman, Kwangmin Choi, Mario A Pujato, Somchai Chutipongtanate, Michael Wyder, Wendy D Haffey, Eric O'B...> ;Science Translational Medicine. 2022 Mar 9
6 citations
Cognitive and behavioral effects of whole brain conventional or high dose rate (FLASH) proton irradiation in a neonatal Sprague Dawley rat model.
Michael T Williams, Chiho Sugimoto, Samantha L Regan, Emily M Pitzer, Adam L Fritz, Mathieu Sertorio, Anthony E Mascia, Ralph E Vatner, John P Perentesis, Charles V Vo...> ;Plos One. 2022 Jan 1
5 citations
Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia.
Shailaja Hegde, Anjelika Gasilina, Mark Wunderlich, Yuan Lin, Marcel Buchholzer, Oliver H.F. Krumbach, Mohammad Akbarzadeh, Mohammad Reza Ahmadian, William L. Seibel, ...> ;Leukemia. 2021 Oct 28
16 citations
Can Rational Combination of Ultra-high Dose Rate FLASH Radiotherapy with Immunotherapy Provide a Novel Approach to Cancer Treatment?
Y. Zhang, Z. Ding, John P. Perentesis, D. Khuntia, Sophia X. Pfister, Ricky A. Sharma> ;Clinical Oncology. 2021 Sep 20
15 citations
The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia
Madeline Niederkorn, Chiharu Ishikawa, Kathleen Hueneman, James Bartram, Emily Stepanchick, Joshua R. Bennett, Ashley E. Culver-Cochran, Lyndsey Bolanos, Emma Uible, K...> ;Leukemia. 2021 Aug 31
3 citations
Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective
Jeremy D. Rubinstein, Rachana Shah, Erin H. Breese, Karen Burns, Jennifer Mangino, Robin E. Norris, Lynn Lee, Benjamin Mizukawa, Maureen M. O'Brien, Christine L Philli...> ;Pediatric Blood & Cancer. 2021 May 21
12 citations
PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia.
Mark Wunderlich, Nicole Manning, Christina Sexton, Eric O'Brien, Luke Byerly, Cody Stillwell, John P. Perentesis, James C. Mulloy, Benjamin Mizukawa> ;Frontiers in Oncology. 2021 Apr 13
2 citations
In Regard to Buchsbaum et al.
John C. Breneman, John P. Perentesis, Jeffrey D. Bradley, Anthony Mascia, Eric Abel, Agam Sharda, Deepak Khuntia, Ricky A. Sharma, Charles B. Simone> ;International Journal of Radiation Oncology, Biology, Physics. 2021 Mar 25
75 citations
FLASH Proton Pencil Beam Scanning Irradiation Minimizes Radiation-Induced Leg Contracture and Skin Toxicity in Mice
Shannon Cunningham, Shelby McCauley, Kanimozhi Vairamani, Joseph Speth, Swati Girdhani, Eric Abel, Ricky A. Sharma, John P. Perentesis, Susanne I. Wells, Anthony Masci...> ;Cancers. 2021 Mar 1
15 citations
A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma
Karen Wright, Xiaopan Yao, Wendy B. London, Pei Chi Kao, Lia Gore, Stephen P. Hunger, Russ Geyer, Kenneth J. Cohen, Jeffrey C. Allen, Howard M. Katzenstein, Amy Smith,...> ;Pediatric Blood & Cancer. 2021 Feb 1
7 citations
Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1‐associated optic pathway gliomas in children
Nicole J. Ullrich, Sanjay P. Prabhu, Roger J. Packer, Stewart Goldman, Nathan Robison, Jeffrey C. Allen, David Viskochil, David H. Gutmann, John P. Perentesis, Bruce R...> ;Pediatric Blood & Cancer. 2021 Apr 1
5 citations
Whole brain proton irradiation in adult Sprague Dawley rats produces dose dependent and non-dependent cognitive, behavioral, and dopaminergic effects.
Michael T. Williams, Chiho Sugimoto, Samantha L. Regan, Emily M. Pitzer, Adam L. Fritz, Anthony Mascia, Mathieu Sertorio, Ralph E. Vatner, John P. Perentesis, Charles ...> ;Scientific Reports. 2020 Dec 9
4 citations
Differential transcriptome response to proton versus X-ray radiation reveals novel candidate targets for combinatorial PT therapy in lymphoma
Mathieu Sertorio, Ali Nowrouzi, Mahdi Akbarpour, Kashish Chetal, Nathan Salomonis, Stephan Brons, Anthony Mascia, Dan Ionascu, Shelby McCauley, Taylor Kupneski, Andrea...> ;Radiotherapy and Oncology. 2021 Feb 1
Join now to see all

Journal Articles

Children's Oncology Group's 2013 blueprint for research: adolescent and young adult oncology.
Freyer DR, Felgenhauer J, Perentesis J; COG Adolescent and Young Adult Oncology Discipline Committee., Pediatr Blood Cancer, 6/1/2013
Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia.
Gamis AS, Alonzo TA, Perentesis JP, Meshinchi S; COG Acute Myeloid Leukemia Committee., Pediatr Blood Cancer, 6/1/2013

Lectures

Predicting Drug Response and Novel Therapeutic Candidates Using Signatures of Molecular Alterations in Hematologic Malignancies
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
In Vitro Approach for the Identification of Exceptional Responders in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

FLASH Proton Therapy Clinical Trial Begins on Cancers Involving Bones in the ChestMarch 28th, 2023
Varian and the Cincinnati Children's/University of Cincinnati Medical Center Proton Therapy Center Announce Promising Results from FAST-01, First-in-Human Clinical Trial of Flash TherapyOctober 24th, 2022
Small Molecule Targets Achilles' Heel of AML, Kills Cancer CellsMarch 16th, 2022
Join now to see all

Grant Support

Molecular Studies Of DOWN Syndrome LeukemiaNational Cancer Institute2005–2008
Genetic Engineering Of Targeted TherapiesNational Cancer Institute1994–1997
Genetic Engineering Of Therapies For Myeloid LeukemiaNational Cancer Institute1993
Molecular Study Of Ribosomal Toxins And ApplicationsNational Institute Of Allergy And Infectious Diseases1987–1991